WO2011083112A3 - Solid oral dosage form containing olmesartan medoxomil - Google Patents

Solid oral dosage form containing olmesartan medoxomil Download PDF

Info

Publication number
WO2011083112A3
WO2011083112A3 PCT/EP2011/050061 EP2011050061W WO2011083112A3 WO 2011083112 A3 WO2011083112 A3 WO 2011083112A3 EP 2011050061 W EP2011050061 W EP 2011050061W WO 2011083112 A3 WO2011083112 A3 WO 2011083112A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
oral dosage
solid oral
olmesartan medoxomil
form containing
Prior art date
Application number
PCT/EP2011/050061
Other languages
French (fr)
Other versions
WO2011083112A2 (en
Inventor
Ganesh V. Gat
Jawed Hussain
Parshwakumar V. Kalyankar
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Priority to CA2785920A priority Critical patent/CA2785920A1/en
Priority to EP11701630.3A priority patent/EP2521540A2/en
Publication of WO2011083112A2 publication Critical patent/WO2011083112A2/en
Publication of WO2011083112A3 publication Critical patent/WO2011083112A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a solid oral dosage form comprising olmesartan medoxomil and polyethylene glycol having a molecular weight of about 1,000 - 10,000.
PCT/EP2011/050061 2010-01-05 2011-01-04 Solid oral dosage form containing olmesartan medoxomil WO2011083112A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2785920A CA2785920A1 (en) 2010-01-05 2011-01-04 Solid oral dosage form containing olmesartan medoxomil
EP11701630.3A EP2521540A2 (en) 2010-01-05 2011-01-04 Solid oral dosage form containing olmesartan medoxomil

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN26DE2010 2010-01-05
IN26/DEL/2010 2010-01-05

Publications (2)

Publication Number Publication Date
WO2011083112A2 WO2011083112A2 (en) 2011-07-14
WO2011083112A3 true WO2011083112A3 (en) 2011-12-29

Family

ID=43795169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/050061 WO2011083112A2 (en) 2010-01-05 2011-01-04 Solid oral dosage form containing olmesartan medoxomil

Country Status (3)

Country Link
EP (1) EP2521540A2 (en)
CA (1) CA2785920A1 (en)
WO (1) WO2011083112A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
CN101066264A (en) * 2007-06-12 2007-11-07 杨喜鸿 Solid olmesartan medoxmil dispersion and its prepn and medicinal application
CN101313907A (en) * 2008-07-07 2008-12-03 北京润德康医药技术有限公司 Medicament composition for treating hyperpiesis
WO2008149338A2 (en) * 2007-06-06 2008-12-11 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
US20060281800A1 (en) 2005-04-12 2006-12-14 Glenmark Pharmaceuticals Limited Polymorphic form of olmesartan and process for its preparation
EP1910343B1 (en) 2005-07-29 2014-10-29 Krka Process for the preparation of olmesartan medoxomil
EP1801111B1 (en) 2005-12-20 2014-07-16 LEK Pharmaceuticals d.d. Novel polymorph forms of olmesartan medoxomil
EP1891952B1 (en) 2006-05-04 2011-10-05 LEK Pharmaceuticals d.d. Pharmaceutical composition of olmesartan medoxomil
GB0710905D0 (en) 2007-06-07 2007-07-18 Generics Uk Ltd Amorphous olmesartan medoxomil

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2008149338A2 (en) * 2007-06-06 2008-12-11 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
CN101066264A (en) * 2007-06-12 2007-11-07 杨喜鸿 Solid olmesartan medoxmil dispersion and its prepn and medicinal application
CN101313907A (en) * 2008-07-07 2008-12-03 北京润德康医药技术有限公司 Medicament composition for treating hyperpiesis

Also Published As

Publication number Publication date
CA2785920A1 (en) 2011-07-14
WO2011083112A2 (en) 2011-07-14
EP2521540A2 (en) 2012-11-14

Similar Documents

Publication Publication Date Title
WO2012076293A3 (en) Formulations comprising polysiloxanes having nitrogen-containing groups
MY166518A (en) Nanocapsules containing microemulsions
GEP20156230B (en) Forms of rifaximin and usage thereof
IL252154A0 (en) Anti-dr5 antibodies, compositions comprising the same and uses thereof
IL216254A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL241634B (en) Novel benzodiazepine derivatives, compositions comprising the same and uses thereof
WO2011088199A3 (en) Stabilization of zinc oxide film in oral compositions
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2011056748A3 (en) Oral compositions for treatment of dry mouth
IL226267A0 (en) Conjugates of an il-2 moiety and a polymer, compositions comprising the same and uses thereof
IL215799A (en) Quinazolone compounds, pharmaceutical compositions comprising the same and uses thereof
MY181898A (en) Heterocyclic compounds and uses thereof
IL204844A (en) Quinolone analogs, pharmaceutical compositions comprising the same and uses thereof
EP2569330A4 (en) Chlorotoxin variants, conjugates, and methods for their use
IL229304A (en) 1',3'-disubstituted- 4- phenyl- 3, 4, 5, 6 -tetrahydro-2h, 1'h - [1, 4'] bipyridinyl- 2'-ones, pharmaceutical compositions comprising them and uses thereof
WO2012040623A3 (en) Nanostructured gels capable of controlled release of encapsulated agents
WO2010138194A3 (en) Immunomodulatory agent-polymeric compounds
IL224288A (en) Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof
IL206808A (en) Indolyl-pyridone derivatives, pharmaceutical compositions comprising the same and uses thereof
WO2011057224A3 (en) Zwitterionic polymer bioconjugates and related methods
IL210549A (en) Substituted- quinoxaline-type bridged-piperidine compounds, compositions comprising them and uses thereof for the manufacture of medicaments
TR201903026T4 (en) S100A4 ANTIBODIES AND THEIR THERAPEUTIC USES.
BR112013015505A2 (en) impact polypropylene copolymer composition, and e.g. loaded compound formulation
IL210316A (en) Triazole derivatives, pharmaceutical compositions comprising the same and uses thereof
MX2010005589A (en) Personal care composition.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11701630

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2011701630

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011701630

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2785920

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE